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Abstract
Background: The mouse C57BL/6 (C57) and DBA/2J (DBA) inbred strains differ substantially in many aspects
of their response to drugs of abuse. The development of microarray analyses represents a genome-wide method
for measuring differences across strains, focusing on expression differences. In the current study, we carried out
microarray analysis in C57 and DBA mice in the nucleus accumbens of drug-naïve and morphine-treated animals.
Results: We identified mRNAs with altered expression between the two strains. We validated the mRNA
expression changes of several such mRNAs, including Gnb1, which has been observed to be regulated by several
drugs of abuse. In addition, we validated alterations in the enzyme activity of one mRNA product, catechol-O-
methyltransferase (Comt). Data mining of expression and behavioral data indicates that both Gnb1 and Comt
expression correlate with aspects of drug response in C57/DBA recombinant inbred strains. Pathway analysis was
carried out to identify pathways showing significant alterations as a result of treatment and/or due to strain
differences. These analyses identified axon guidance genes, particularly the semaphorins, as showing altered
expression in the presence of morphine, and plasticity genes as showing altered expression across strains.
Pathway analysis of genes showing strain by treatment interaction suggest that the phosphatidylinositol signaling
pathway may represent an important difference between the strains as related to morphine exposure.
Conclusion: mRNAs with differing expression between the two strains could potentially contribute to strain-
specific responses to drugs of abuse. One such mRNA is Comt and we hypothesize that altered expression of
Comt may represent a potential mechanism for regulating the effect of, and response to, multiple substances of
abuse. Similarly, a role for Gnb1 in responses to multiple drugs of abuse is supported by expression data from
our study and from other studies. Finally, the data support a role for semaphorin signaling in morphine effects,
and indicate that altered expression of genes involved in phosphatidylinositol signaling and plasticity might also
affect the altered drug responses in the two strains.
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Background
The mouse C57 and DBA inbred strains differ substan-
tially in many aspects of their response to drugs of abuse,
including altered rates of voluntary drug consumption
[1]. The C57 strain shows increased voluntary consump-
tion of multiple drugs of abuse, including opiates, alco-
hol, cocaine, and amphetamine, which mirrors the poly-
substance nature of some drug-seeking behavior in
humans [2,3]. C57 strains of mice have been viewed as a
good model for human drug-seeking behavior. It has been
assumed that the poly-substance nature of drug-seeking in
C57, as compared to DBA, is due, in part, to common
mechanisms that operate irrespective of the drug of abuse.
This assumption is fueled by studies showing that there
are susceptibility factors that contribute to drug use irre-
spective of the substance, as well as susceptibility factors
that are specific to each pharmacologic class [2-4].
Multiple quantitative trait locus analyses (QTL) have been
carried in the C57 and DBA strains for both drug
responses and drug-seeking behavior. QTL analyses for
drug-seeking preferences to different classes of drugs
might identify regions of the genome associated with
drug-seeking across multiple pharmacological classes and,
perhaps, more directly target common reward pathways
for multiple substances. For morphine, the strongest evi-
dence for a QTL underlying morphine preference is on the
proximal part of chromosome 10, at the position of the
mu opiate receptor [5-7]. In the case of preference for
alcohol, the strongest QTL's are on chromosomes 2, 3, 4,
and 9, as determined by meta-analyses of 8 studies of
alcohol preference [8]. Further studies with other sub-
stances need to be carried out to determine regions of
potential overlap. The development of microarray analy-
ses represents an additional genome-wide method for
measuring differences across strains, focusing on expres-
sion differences rather than on sequence differences in the
genome. This is an additional approach to characterize
variations between strains as a means of understanding
molecular differences that might underlie strain variabil-
ity in the effect of, and response to, multiple substances of
abuse.
In the current study, we have carried out microarray anal-
ysis in C57 and DBA mice in the nucleus accumbens
(NAC) of naïve and drug-treated animals. We identified a
number of mRNAs with altered expression between the
two strains. We validated the mRNA expression changes
of several such mRNAs, as well as the protein activity of
one mRNA product, catechol-O-methyltransferase
(Comt). Data mining of expression and behavioral data
indicates that Comt expression correlates with two aspects
of drug response in C57/DBA recombinant inbred strains.
Similarly, a role for Gnb1 in responses to multiple drugs
of abuse is supported by data from our study and from
other studies. Specific pathways were also identified that
showed effects of treatment and/or strain. mRNAs with
differing expression between the two strains could poten-
tially contribute to strain-specific responses to drugs of
abuse.
Results
Microarray analysis in the nucleus accumbens
We carried out microarray analysis in the dissected NAC
from 9 vehicle-treated and 9 morphine-treated C57 and 9
DBA mice, using a pooling strategy to minimize dissec-
tion and other variations. Twelve groups of 3 NAC were
hybridized to the Affymetrix MG_U74A microarray and
the resultant data analyzed using dChip. We compared
mRNA expression between strains, and across treatment
groups.
The first analysis was gene oriented, and required a signif-
icant (>= 1.7) fold change and made use of t-testing to
ascribe significance (P < 0.05) (see Methods). Comparing
mRNA expression between C57 and DBA mice in the
absence of morphine, we identified 67 mRNAs with
altered expression, four (cathepsin e/Cathe, integrin beta
1 binding protein 1/Itgb1bp1, zinc finger protein 97/
Zfp97, and the riken cdna 1110008e19 gene/glyoxalase 1/
Glo1) with two different probe sets [see Additional file
Table 1A]. Comparing mRNA expression between the two
strains in the presence of morphine (via pellet) for 4 days,
we identified 50 mRNAs with altered expression, four
(Itgb1bp1, Glo1, guanine nucleotide binding protein,
beta 1/Gnb1, and transcription elongation factor a (sii) 1/
Tcea1) with two different probe sets [see Additional file
Table 1B]. We also compared expression within each
strain, contrasting expression in vehicle and morphine-
treated mice [see Additional file Table 1C]. There were
fewer morphine-responsive mRNAs within each of the
two strains, when compared to the number of mRNAs
that differed between strains. In the DBA strain, 8 mRNAs
were identified as changed with an effect >= 1.7 fold in
response to morphine and we did not identify any mRNAs
showing a P < 0.05 and greater than >= 1.7 fold change in
the C57 strain in response to morphine.
Treatment-invariant mRNAs
It was of interest that genes showing greater expression
changes in these first analyses were much more common
across strains than within strains. Furthermore, there was
a very significant proportion of mRNAs that showed
altered expression between the two strains in both the
drug-naïve and the morphine-treated groups [see Addi-
tional file Table 1, A, B]. We examined the correlation of
the fold-expression changes of these treatment-invariant
mRNAs under the two treatments and observed a linear
relationship, with a high degree of correlation in the rela-
tive expression of these mRNAs (correlation coefficient ofBMC Genomics 2007, 8:76 http://www.biomedcentral.com/1471-2164/8/76
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>0.98). These treatment-invariant mRNAs were of partic-
ular interest as they represent a molecular environment
that is consistently different between the two strains, irre-
spective of treatment condition. They also provide evi-
dence that the microarray studies are internally consistent.
Two-way ANOVA
The presence of a large proportion of mRNAs that showed
altered expression irrespective of treatment supported fur-
ther analysis of the dataset, using two-way ANOVA. With
such an approach, we could identify mRNAs showing
main effects for strain, main effects for treatment, and
interaction effects. We used more permissive criteria (no
fold-effect requirement, but P < 0.01), so as to capture
genes and pathways that demonstrated smaller but signif-
icant changes in expression. Running such analyses led to
the identification of 973 genes that showed a main effect
of strain, 185 genes showing a main effect of treatment,
and 326 genes showing significant interaction effects [see
Additional file Table 2A–C].
Gnb1 showed the most significant (P = 1.65 × 10-10) main
effect for strain and additional treatment-invariant genes
noted above (including Comt, P = 2.14 × 10-7) were also
identified in this analysis. KEGG pathway analyses of
genes showing main effect for strain identified clusters of
genes associated with the ribosome, oxidative phosphor-
ylation/ATP synthesis, long-term potentiation/long-term
depression, and antigen processing and presentation [see
Additional file Table 3A].
KEGG pathway analysis of genes showing a main effect of
treatment [see Additional file Table 2B] identified two sig-
nificant functional groups, including "axon guidance"
[see Additional file Table 3B]. The axon guidance group of
genes identified in these analyses were all related to the
semaphorin pathway [see Additional file Table 2, B and
Additional file Table 3B, as well as Discussion]. KEGG
pathway analysis of genes showing significant strain by
treatment interactions [see Additional file Table 2C] iden-
tified significant effects for genes in the focal adhesion
pathway, particularly genes involved in phosphatidyli-
nositol signaling system [see Additional file Table 2C and
Additional file Table 3C, as well as Discussion].
Validation of microarray analyses
We chose a selection of the mRNAs from the microarray
studies for follow-up using quantitative polymerase chain
reaction (QPCR) to validate the microarray signals.
mRNAs were chosen to represent both the up-regulated
and down-regulated mRNAs, to represent mRNAs show-
ing more profound expression changes, to represent
mRNAs with neuronal expression (analyzed by reviewing
the expression of each probe set in mouse tissue [9]) and/
or potentially relevant neuronal function, and based on
other published studies on either varying expression in
mouse strains or changes in response to drugs of abuse.
We were able to validate a majority of mRNAs for which
we carried out QPCR, as shown in Table 1. Overall valida-
tion of the microarray results was reflected in the high cor-
relation of the ratio of mRNA expression between the two
strains as measured by microarray and by QPCR (Pear-
son's correlation coefficient, r>0.8, examining vehicle-
treated mice). Furthermore, by ANOVA there was a signif-
icant (P < 0.05) main effect of strain with actin related
protein 2/3 complex, subunit 5/Arpc5, Comt, Gnb1,
phosphodiesterase 9a/Pde9a, phosphatidylinositol trans-
fer protein, beta/Pitpnb, and secretory granule neuroen-
docrine protein 1, 7B2 protein/Sgne1, and a significant
main effect of treatment with Arpc5, and Rcn. There was a
trend level (P < 0.10) main effect of strain with Rcn, and a
trend level main effect of treatment with Gabra2. Finally,
there were significant interaction terms with Arpc5, ngfi-a
binding protein 2/Nab2, and Rcn. Not all microarray
results were unambiguously validated, as an mRNA show-
ing great dys-regulation between the two strains by micro-
array (Pitpnb) did not show such profound alterations in
expression by QPCR. Failure of validation can occur for
several reasons, including differing probes used for the
microarray and QPCR experiments (which can capture
differential expression in splice variants), genomic differ-
ences between strains that alters the hybridization of the
relevant regions of the probes, and false-positive expres-
sion changes.
Comt levels and morphine
A recent report made the observation that individuals
with a Met/Met genotype (associated with significantly
decreased COMT activity) at the Val158Met polymor-
phism of the human COMT gene required a significantly
reduced dose of morphine to achieve pain relief, as com-
pared to individuals with the Val/Val genotype [10]. These
observations are consistent with other studies implicating
COMT activity with opioid response [11,12]. Since the
DBA mice showed increased sensitivity to morphine com-
pared to C57, as defined by the tail flick assay, and reduc-
tion in Comt expression and activity, we sought to
determine the degree to which morphine sensitivity var-
ied in C57/DBA recombinant inbred strains, as a function
of Comt expression, making use of the WebQTL database
[13]. We first noted that in those studies of whole brain
homogenates, Comt expression was significantly
decreased in DBA, as compared to C57, consistent with
our studies in the NAC. We then examined the indices of
morphine effect described above. Slope of the dose-
response curve and the response to 16 mg/kg of morphine
both correlated with levels of Comt expression (rank
order correlations of -0.535, P = 0.0076, and -0.470, P =
0.026, respectively) (Figure 1). Comt expression did notBMC Genomics 2007, 8:76 http://www.biomedcentral.com/1471-2164/8/76
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show significant correlation with morphine consumption
in a two-bottle choice paradigm (rank order correlation of
0.356, P = 0.104).
The correlation of Comt expression with two indices of
morphine effect suggested a possible relationship
between these two measures in mice. As mRNA levels do
not always correlate with protein levels and protein activ-
ity, we next sought to determine whether Comt activity
differed in brain extracts from C57 and DBA mice. NAC,
amygdala (AMY), and frontal cortex (FC) were dissected
from DBA and C57 mice and Comt activity was then
determined in homogenates. Comt activity was modestly,
but significantly, reduced in NAC (p = 0.01) and FC (p =
0.002) of DBA mice, as compared to C57 mice (Figure 2).
Discussion
We examined mRNA expression in the NAC in vehicle- or
morphine-treated mice, comparing the C57 and DBA
strains. The NAC is part of the mesocorticolimbic
dopamine system which originates in the ventral tegmen-
tal area (VTA) and projects to the NAC, FC and other lim-
bic areas [14]. The VTA and the NAC are two brain regions
commonly thought to be involved in the reward system
for drugs of abuse. In studies that compared gene expres-
sion changes induced by morphine treatment across mul-
tiple brain regions, the NAC shows some of the most
profound changes in the total number of genes with
altered expression in the presence of drug (e.g., [15]).
In the current study, we made use of an established and
well-regarded analytical platform for analysis of microar-
rays. In our first analyses, we required reasonable levels of
expression, a modest (>= 1.7) fold change, and a nominal
P < 0.05. Median False-Discovery Rate (FDR) estimates
were between ~1–4% for results contrasting the two
strains, but were significantly higher (~20% for DBA) for
contrasts within strains [see Additional file Table 1A–C].
Of importance to the current study is that Kerns et al. have
recently compared mRNA expression in the NAC in con-
trol C57 and DBA animals [16]. Of the 67 mRNAs show-
ing altered expression in our study of vehicle-treated mice,
more than 20 (some of which, including Gnb1, Itgb1bp1,
and Glo1, with two probes) were also observed to show
altered expression (>1.7 fold change) in the Kerns study,
in the same direction for the same probe sets, using differ-
ent analytical methods (additional probe sets show
altered expression of 1.4–1.7 fold change in the Kerns
study, in the same direction). Furthermore, there was a
significant agreement in relative mRNA expression across
the two studies (correlation coefficient of ~0.8). This indi-
cates that a significant proportion of mRNAs showing
altered expression by microarrays can be reproduced
across the two studies, irrespective of analytical approach.
It also represents an important validation of such micro-
array studies.
While the Kerns study did not identify changes in Comt,
our analysis of an independent dataset supported our
results. In addition, microarray studies in the hippocam-
pus of eight mouse strains demonstrated highest expres-
sion of Comt in C57, amongst all the strains (including
DBA), and a significant inverse correlation of Comt
expression with aggressive behaviors [17]. This same
study identified a decrease in expression of Riken cDNA
1810037i17 in C57, compared with DBA, and a positive
correlation of expression of this gene with aggressive
behaviors. In the current study we observed increased
expression of Comt in C57, as compared to DBA, and
increased expression of 1810037I17Rik in DBA, with a
very significant main effect of strain (P = 7.83 × 10-7).
More generally, several genes showing altered expression
in controls in our study (including Prdrx2, Comt, Zfp197,
Gabra2, Gnb1, Sgne1, Glo1, and additional ESTs) also
showed similar alterations in that study, when analyzed
with both MAS5 and dChip, even though the focus was on
an independent brain area.
Table 1: QPCR validation analysis of select neuronal mRNAs.
C57 Control C57 Morphine DBA Control DBA Morphine
Arpc5*+! 1.00 0.13 1.42 ± 0.19 5.48 ± 0.38 13.61 ± 0.23
Comt* 1.00 ± 0.09 1.68 ± 0.39 0.71 ± 0.20 0.64 ± 0.05
Gabra2 1.00 ± 0.20 2.38 ± 0.34 3.99 ± 0.40 2.67 ± 0.62
Gnb1* 1.00 ± 0.10 1.46 ± 0.36 7.85 ± 0.22 12.13 ± 0.12
Nab2! 1.00 ± 0.10 1.28 ± 0.33 1.25 ± 0.36 0.41 ± 0.05
Pde9a* 1.00 ± 0.05 1.03 ± 0.06 2.04 ± 0.41 2.66 ± 0.31
Pitpnb* 1.00 ± 0.07 0.94 ± 0.05 0.34 ± 0.42 0.37 ± 0.15
Rcn+! 1.00 ± 0.03 6.18 ± 0.92 3.27 ± 0.81 1.47 ± 0.27
Sgne1* 1.00 ± 0.12 0.99 ± 0.07 3.88 ± 0.32 2.59 ± 0.19
Nucleus accumbens (NAC) from vehicle or morphine (4 d) treated C57 or DBA mice were dissected and used for QPCR analysis. Eight neuronal 
mRNAs are profiled above, showing for each mRNAs the expression in C57 control, C57 with morphine, DBA control, and DBA with morphine, 
always normalized to the average expression in C57 control. Data represent means ± SEM of expression normalized to the average expression in 
C57 under control conditions. *, P < 0.05 for main effect of strain; +, P < 0.05 for main effect of treatment; !, P < 0.05 for interaction.BMC Genomics 2007, 8:76 http://www.biomedcentral.com/1471-2164/8/76
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Microarrays are very important tools for exploratory anal-
yses, but have some important restrictions. Samples run
on different platforms (e.g., [18]), or analyzed with differ-
ent methods (e.g., [19-22]), can produce varying results.
Quality of probes, probes directed at minor splice vari-
ants, and mis-annotation of probes can also lead to errors
in conclusions (e.g., [23]). Furthermore, for a proportion
of mRNAs with altered expression, there may not be a cor-
responding change in protein expression. For all of these
reasons, validation by additional methods is critical. In
recent QPCR analyses of striata from four strains of mice,
Comt was found to be downregulated in DBA, as com-
pared to C57 [24], consistent with the microarray, QPCR
and enzyme activity results presented here. Similarly,
Gabra2 was observed to be upregulated in DBA, as com-
pared to C57, in that study as well.
A common mechanism for many drugs of abuse is the
increase of dopamine in the pathway from the VTA
through the NAC and to the FC [25]. In the case of mor-
phine, binding of morphine to GABA interneurons
reduces GABA release, thereby reducing the GABA-medi-
ated inhibition of dopamine release in the NAC, with a
net result of increasing dopamine levels. In the case of
cocaine, blocking of dopamine re-uptake leads to
increased dopamine levels, while in the presence of
amphetamine, there is increased non-vesicular release of
dopamine. Additional studies implicate these pathways in
the responses to other substances of abuse. Elevation of
dopamine would be inhibited by increased activity of
Comt. We, therefore, can hypothesize that animals, or
humans, with elevated Comt levels would experience
reduced rewarding effects to drugs of abuse, while animals
or humans with decreased levels of Comt may be more
sensitive to certain drugs of abuse and perhaps even find
them aversive. Alternatively, elevated Comt levels may
lead to a hypo-dopamine state which drug taking might
alleviate.
In several studies in human substance use, there has been
evidence for an association of COMT genotype with sub-
stance use (reviewed in [26]). While these studies remain
somewhat controversial, they are consistent with our
hypotheses. These studies typically focused on the Val/
Met variant in COMT. However, it may be that analysis of
other variants within COMT, such as those associated
with expression [27], may show stronger association with
substance use.
A corollary of our hypotheses is that reduction of Comt
activity, by the use of Comt inhibitors, may have two
important effects. In the case of analgesia for severe pain,
Comt inhibitors may reduce the levels of analgesics
required, an hypothesis with some empirical support
[10]. In addition, in instances of drug seeking behavior,
Correlation of brain Comt and Gnb1 expression with mor- phine efficacy Figure 1
Correlation of brain Comt and Gnb1 expression with 
morphine efficacy. Comt and Gnb1 expression in BXD RI 
strains were correlated with the slope of the morphine dose-
response curve (a, n = 23) (derived from [51]), with the anal-
gesia observed with 16 mg/kg of morphine (b, n = 22) (anal-
gesia is expressed as percent of maximum effect and is 
derived from Fig. 1 of [52]), or with morphine consumption 
in a two-bottle choice study (c, n = 22) [53] in the BXD RI 
strains. All expression and behavioural data can be found on 
the WebQTL database [13]. Comt expression was assessed 
using the single associated probe set (98535_at), while Gnb1 
expression was assessed using probe set 94854_g_at. Rank 
order correlations were: Top, -0.535, P = 0.0076; middle, -
0.470, P = 0.026; and, bottom, -0.586, P = 0.0035.
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Comt inhibitors may reduce drug seeking by reducing the
"hypo-dopamine state," and/or by making the drug aver-
sive or less rewarding. Studies on Comt in animals have
previously demonstrated that non-specific COMT-inhibi-
tors, when given in the presence of morphine, can be
lethal [28,29]. While these results might suggest that there
is an important molecular interaction between Comt and
drugs of abuse, it is important to note that these studies
were carried out with less specific, first generation COMT
inhibitors.
Gnb1, one mRNA of a group of differentially expressed
genes that we identified as also having enriched expres-
sion in the brain, showed significant correlation with
morphine consumption in a two-bottle choice paradigm.
Gnb1 was represented by three probe sets on the microar-
ray that showed significant correlation with each other
(rank order correlation 0.594–0.831, P 1.33 × 10-11-1.08
× 10-04). Correlation of the Gnb1 probe sets with mor-
phine consumption showed rank order correlations of -
0.586 (P = 0.0035; Fig. 1), -0.458 (P = 0.031), and -0.381
(P = 0.080), for probe sets 94854_g_at, 94853_at, and
97458_at, respectively. Altered expression of Gnb1 was
confirmed by QPCR. All three probe sets of Gnb1 were
observed to have decreased expression in the DBA strain
under control conditions in the NAC in an independent
study [16]. Moreover, in that study Gnb1 also showed
decreased expression in the FC in the DBA strain. Finally,
Gnb1 (examining probe set 94853_at) was previously
shown to have a five-fold range of expression in BXD
recombinant inbred strains, with a heritability of 75%,
which is near the maximum observed for any transcript
[30]. Gnb1 is a beta-subunit for the heterotrimeric gua-
Enzymatic assay of Comt activity in DBA and C57 strains Figure 2
Enzymatic assay of Comt activity in DBA and C57 strains. Nucleus accumbens (NAC), amygdala (AMY), and frontal 
cortex (FC) were dissected from DBA and C57 mice, and Comt activity was determined in homogenates, as described in the 
methods. *, P = 0.01; **, P = 0.002.
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nine nucleotide-binding proteins, and is also known to
play an important role in the visual system.
In our studies, Gnb1 expression, as measured by QPCR,
showed modestly increased (~50%) expression in both
strains in the presence of morphine. Interestingly, Gnb1
expression has been shown to be up-regulated in the NAC
in response to cocaine administration in mouse [31] and
rat [32], and in response to amphetamine [31] and meth-
amphetamine [33] treatment in the mouse. Antisense dis-
ruption of Gnb1 expression blocks cocaine-induced
sensitization, but without affecting the acute responses to
cocaine [31]. In a recent study examining genes that show
altered expression four hours after naltrexone-induced
morphine withdrawal, Gnb1 was downregulated in the
locus coeruleus (LC) of C57 mice [34]. The LC is the pri-
mary site of noradrenergic neurons in the brain, and sends
projections throughout the mesocorticolimbic dopamine
system, including to the NAC, VTA, and FC, and is a medi-
ator of physical dependence on opiates [14]. Gnb1 maps
to murine chromosome 4 (at 15 Mb) and GNB1 maps to
human chromosome 1p36.33. A role for Gnb1 expression
in responses to multiple drugs of abuse is supported by
the expression data.
By the nature of our experimental design, we were able to
consider strain and treatment effects in the same study.
Such an approach has not been undertaking previously.
There were multiple genes showing main effects of strain
with much more modest numbers of genes showing main
effects of treatment or strain by treatment interactions.
One facet of our results is consistent with the hypothesis
that an important determinant underlying the differences
in morphine response across strains lies in genes that
show a main effect of strain and are not necessarily regu-
lated by morphine. Such genes include Gnb1 and Comt,
as discussed in detail above. Other genes showing main
effects of strain are genes important in plasticity, includ-
ing those defined in the KEGG pathways of long-term
potentiation (LTP) and long-term depression (LTD).
Genes in these pathways that show a main effect of strain
by ANOVA include an ionotropic glutamate receptor sub-
unit (NMDA2B), two isoforms of calcium/calmodulin-
dependent protein kinase II (CaMKII), phosphatases
[protein phosphatase 3/calcineurin (CaN) and protein
phosphatase 2 (formerly 2A)], an inositol 1,4,5-triphos-
phate receptor (IP3R), ras proteins (Ras), and a mitogen
activated kinase in the LTP pathway. In the LTD pathway,
KEGG analysis identified several guanine nucleotide
binding protein (G protein) subunits, phospholipase A2,
the mitogen activated kinase, protein phosphatase 2 and
IP3R identified above, as well as insulin-like growth factor
1. These plasticity genes may contribute to multiple differ-
ences between the strains, including to drug responses. In
this context, the genes identified in the long-term potenti-
ation pathway are interesting. The NMDA receptor modu-
lates intracellular calcium levels, as does IP3R. This in turn
can modulate calcium dependent protein phosphatases,
kinases and ras proteins, followed by changes in activity of
mitogen activated kinases. Expression of representatives
of all of these classes of enzymes are altered across the two
strains, and may thereby contribute to altered drug
dependence (e.g., [35]).
Genes showing a main effect of treatment are related to
morphine response, irrespective of strain. These genes fell
into a diverse group. KEGG analysis identified two signif-
icant groups, identified as "adipocytokine signaling path-
way" and "axon guidance." The axon guidance group of
genes identified in KEGG analysis were all related to the
semaphorin pathway, with semaphorins 3F, 4B, 6C, 6D,
and 7A showing treatment effects. A potential semaphorin
receptor, plexin A3, was also identified as showing a main
effect of treatment. This is an interesting finding in light of
a recent study looking at the effects of cocaine on sema-
phorins and other axon guidance molecules in adult rat
[36]. Many of the semaphorins, including those above,
showed significant expression changes in response to
cocaine. Although that study made use of cocaine, it may
be that changes in axon guidance molecules are a frequent
response to drugs of abuse (see [37]).
Another aspect of the drug by strain analysis allows for
looking at genes that are differentially regulated across
strains in response to morphine. These genes may also
contribute to altered drug response between C57 and DBA
mice. KEGG analysis identified genes within the focal
adhesion pathway as showing drug by strain interactions
in ANOVA. Several extracellular matrix (ECM) genes (col-
lagen and laminins) were identified, as were two integrins
(beta5 and alpha2), which can bind to ECM proteins.
Genes downstream of the integrins, including phosphati-
dylinositol 3-kinase (PI3K), were altered, as well as genes
regulated by the phosphatidylinositol signaling system
(3-phosphoinositide dependent protein kinase and Vav
oncogene). These results suggest that the phosphatidyli-
nositol signaling system is of interest in individual varia-
tions in drug responses, especially considering that there
is recent evidence for a role for this system in morphine
withdrawal and cocaine sensitization [38,39].
QTL analysis, as a means for understanding molecular dif-
ferences across strains, has proven more difficult than
anticipated. As elaborated in a recent review [40], over the
past 15 years, there have been more than 2,000 QTLs that
have identified in crosses between inbred strains of mice,
and 700 QTLs found in crosses between inbred strains of
rats. However, only about 20 genes have been identified
from these QTL analyses, many of which have LOD scores
of over 10. The overall success rate of less than 1% forBMC Genomics 2007, 8:76 http://www.biomedcentral.com/1471-2164/8/76
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identifying genes underlying QTLs has been explained by
various means, and likely reflects a hidden complexity in
the QTL analyses. The use of microarrays to supplement
QTL analyses may simplify the identification of quantita-
tive trait genes (QTGs) that underlie QTLs and may also
identify additional genes that have not been mapped by
QTL analysis. It is of note that QTL analyses of drug-
related behavior in mice will not necessarily identify the
Comt, Gnb1 or other loci. However, it is important to
appreciate that genetic factors modulating expression of a
given gene can localize either to the gene (cis) or to other
loci in the genome (trans). For example, expression QTL
(eQTL) analysis of murine Comt, using the UTHSC web-
site [41] demonstrate suggestive (>2.27) LOD scores near
the Comt locus (at 20 Mb), but also at murine chromo-
some 10 (105–110 Mb).
Conclusion
In summary, there are multiple mRNAs that show differ-
ential expression between the C57 and DBA strains. Of
them, we highlight Comt and Gnb1 as potentially con-
tributing to altered drug-related behaviors in C57 as com-
pared to DBA mice. We suggest that inhibition of Comt by
pharmacological methods may reduce desire for drugs
and perhaps cause them to be more effective in clinical
settings and/or less rewarding in non-clinical settings.
Pathway analysis highlights important differences
between the two strains with regards to plasticity (LTP and
LTD), which may contribute to some of the behavioral
differences across the strains, including those associated
with drug-related behaviors. Furthermore, pathway analy-
sis supports a role for semaphorin signaling in morphine
effects, and indicates that altered expression of genes
involved in phosphatidylinositol signaling and plasticity
might also affect the altered drug responses in the two
strains.
Methods
Mice
Mice were obtained from the Jackson Laboratory. Animals
were male, 8–12 weeks old, with a weight range of 18 to
28 grams. Animals underwent surgery for subcutaneous
implantation of either a control or morphine pellet
(either the "Placebo to Morphine Base Implant Pellet" or
the 25 mg "Morphine Base Implant Pellet," both the kind
gift of the National Institute on Drug Abuse) on the dorsal
aspect of the neck. The composition of the pellets was
identical (microcrystalline cellulose, 149 mg; magnesium
stearate, 1.5 mg; colloidal silicon dioxide, 2.5 mg) except
for the addition of 25 mg of purified morphine. While the
animal was under anesthesia (ketamine-HCl and xyla-
zine), a 1/4-inch slit was made in the skin, the pellet
inserted and the area closed with a surgical metal staple.
Morphine-treated mice from both strains demonstrated
dorsiflexion of the tail (Straub tail). Consistent with pre-
vious results [42], there appeared to be increased home
cage locomotion in morphine-treated C57 mice. We
implanted the pellet on Day 1 and sacrificed on Day 5.
Euthanasia was carried out using CO2 with cervical dislo-
cation, and the brains rapidly dissected. Thick sections
(500–600 μm) were sliced on a Vibratome, and the struc-
tures (frontal cortex, amygdala, and nucleus accumbens)
were dissected from these sections under a dissecting
scope, using delineations and stereotaxic coordinates
from a mouse brain atlas [43]. The caudal aspect of frontal
cortex was defined by the level at which the genu of the
cortex collosum became visible. The animal protocol was
approved by the Coatesville VA Medical Center IACUC.
Microarrays
Nucleus accumbens was dissected from nine C57 and
nine DBA male mice. Tissue was then pooled into groups
of three samples, as a means of minimizing variation due
to dissection. RNA was purified using Trizol reagent
(Gibco), and RNA quality was confirmed by 260/280
ratio, and by subsequent analysis on an Agilent Bioana-
lyzer. Between 1 and 10 μg of total RNA from each sample
was used to generate a high fidelity cDNA, which is mod-
ified at the 3' end to contain an initiation site for T7 RNA
polymerase. Upon completion of cDNA synthesis 1 μg of
product was used in an in vitro transcription (IVT) reac-
tion that contains biotinylated UTP and CTP utilized for
detection following hybridization to the oligonucleotide
microarray. 20 μg of full-length cRNA was fragmented in
200 mM Tris-actetate (pH 8.1), 500 mM KOAc and 150
mM MgOAc at 94C for 35 minutes. Following fragmenta-
tion all components generated throughout the processing
procedure (cDNA, full-length cRNA, and fragmented
cRNA) were analyzed by electrophoresis using the Agilent
Bioanalyzer 2100 to assess the appropriate size distribu-
tion prior to microarray hybridization. Detailed protocols
for sample preparation using the Affymetrix labeling pro-
tocols can be found at [44].
Samples were subjected to hybridization against the
Affymetrix U74A high-density oligonucleotide array.
Hybridization, staining and washing of all arrays was per-
formed in the Affymetrix fluidics module as per the man-
ufacturer's protocol. Streptavidin phycroerythrin stain
(SAPE, Molecular Probes) was the fluorescent conjugate
used to detect hybridized target sequences. The detection
and quantitation of target hybridization was performed
with a GeneArray Scanner (Hewlett Packard/Affymetrix)
set to scan each array twice at a factory set PMT level and
resolution. Arrays were assessed for "array performance"
prior to data analysis. This process involves the statistical
analysis of control transcripts that are spiked into the sam-
ples and the hybridization cocktail to assess consistency of
signal quality. Samples met a minimum set of standards
in order for the array (and the sample) to be included inBMC Genomics 2007, 8:76 http://www.biomedcentral.com/1471-2164/8/76
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downstream analysis. All arrays had 3'/5' ratios (for BAC-
TIN and GAPDH) of less than 2.5, indicating a lack of bias
in the RT and cRNA amplification process. All arrays
achieved a % present call rate of 45% or greater.
The dChip algorithm (version 1.3) was used to analyze all
microarray data [45]. dChip takes advantage of the high
degree of standardization of oligonucleotide arrays to deal
with two recurrent problems with oligonucleotide arrays.
The first problem is the large differences that often exist in
results obtained with different probes to the same mRNA.
The second is the inevitable presence of large or small
regions of contamination on any given array. Because the
synthesis of the arrays is so standardized, the behavior of
each probe is highly reproducible and predictable. Thus
using modeling and appropriate analysis, the relative reli-
ability of a probe can be estimated and a weighted index
of expression can be determined (a model-based expres-
sion index, or MBEI). The MBEI has a standard error asso-
ciated with it as a measure of accuracy. Furthermore,
probe sets within an mRNA that, for a particular experi-
ment, show profiles that deviate significantly from the
typical profile, can be automatically flagged as likely
reflecting contamination or cross-hybridization. As a pri-
mary analysis, we used Invariant Set Normalization and
PM-MM modeling [45], with a threshold of 1.7-fold
change, a nominal p value < 0.05, a percent call of >80%,
and an absolute differences in expression of > 50 (to elim-
inate mRNAs that were expressed at near-background
level) to choose genes for further analysis. The nominal p
value was determined using dChip (which down-weights
unreliable expression data), testing whether the mean dif-
ference between two groups equals to zero by the
unpaired t-test. False discovery rates (FDR) for each pair of
datasets contrasted were empirically estimated with 200
random permutations of the data.
Given the clear evidence for treatment-invariant genes
(see Results) in these first analyses, we also carried out
two-way analysis of variance (ANOVA) using dChip, iden-
tifying genes with a main effect of strain or treatment, or
with an interaction effect. Here the requirement was sim-
ply a P < 0.01. This less conservative analysis identified
many more genes, and Gene Ontology as well as Kyoto
Encyclopedia of Genes and Genomes [46] pathway analy-
sis was carried out to identify classes of genes and path-
ways that were particularly affected.
Annotation, Gene Ontology, and KEGG pathway analyses
were carried out with DAVID (Database for Annotation,
Visualization and Integrated Discovery 2007, [47]). Raw
microarray data from this study is available on the NCBI
GEO website.
Real time quantitative RT-PCR (Q-PCR)
Nucleus accumbens was dissected from male C57 and
DBA mice that had been treated for 4 days with either a
control or a morphine pellet. mRNA expression was
examined using Taqman chemistry. We acquired com-
mercially validated assays from ABI for gene expression
analysis. The assay ID's for the genes interrogated are as
follows: Arpc5, Mm00848130; Comt, Mm005714377;
Gnb1, Mm00515002; Nab2, Mm00476267; Pde9a,
Mm00501039; Pitpnb, Mm01205388; Sgne1,
Mm00486077; and Rcn, Mm00485644. The following
dye combinations for probe generation were used for
detection and data normalization: FAM (for the mRNAs
of interest), HEX (for GAPDH, as a normalizer mRNA)
and BHQ1 (non-fluorescent quencher) and ROX (refer-
ence). GAPDH was selected as a reference mRNA for com-
parative analysis based on its behavior in the microarray
data set, showing no signal value differences in different
strains. Following probe and primer optimization all
cDNA's were diluted and used in a 10 μl PCR reaction
containing: 5 μl of ABI 2x Universal Master Mix, 1.25 μl of
each forward and reverse primers (final concentrations
ranging from 200–900 nM depending on the primer set),
1 μl of probe (final concentrations ranging from 50–200
nM depending on the probe/primer set) and RNAase/
DNAase free water. All reactions were performed in tripli-
cate. Reactions were run in an ABI 7900 with the follow-
ing cycle parameters: 1 cycle of 50°C (2 min) followed by
95°C (10 min.), 40 cycles of 95°C (15 sec) followed by
60°C (1 min). Data were collected at every temperature
phase during every cycle, and analyzed using the
Sequence Detection Software (ABI, Foster City CA). Rela-
tive quantitation using the comparative threshold cycle
(CT) method was performed in Microsoft Excel (ABI Tech-
note #2: Relative Gene Expression Quantitation). Real-
time quantitative PCR P-values were calculated using two-
way ANOVA carried out independently for each gene tar-
get.
Enzymatic analysis of Comt
Nucleus accumbens, amygdala, and frontal cortex were
dissected from male C57 and DBA mice. Assay of Comt
was carried out as described earlier [48], with 500 μM sub-
strate, instead of 240 μM.
Analysis of mRNA expression as a function of morphine 
response
We made use of the April 05 data freeze, providing esti-
mates of mRNA expression in brains of C57BL/6JXDBA/2J
recombinant inbred mice, generated at the University of
Tennessee Health Science Center (UTHSC) [41]. In order
to be consistent throughout our own studies, which made
use of the Affymetrix U74Av2 microarrays we made use of
data measured using the same microarrays. At UTHSC,
over 300 brain samples from 35 strains were hybridized inBMC Genomics 2007, 8:76 http://www.biomedcentral.com/1471-2164/8/76
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small pools (n = 3) to 100 arrays. Data were processed
using the S-score software [49,50], although other analy-
sis methods produced equivalent results. The S-score
method centers expression of every probe set at 0. The sig-
nal values are therefore strain deviations in Z score units
from the grand mean based on all arrays. For phenotype
data, we made use of the data from published studies that
characterized the morphine analgesia dose-response curve
slope, hot plate analgesia in response to 16 mg/kg mor-
phine, or morphine consumption in a two-bottle choice
paradigm [51,52].
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